CO5210906A1 - IMUNOGENS CONTAINING PEPTIDES FROM DOMINO CE2 DE IgE FOR THE TREATMENT AND PREVENTION OF ALLERGIC DISEASES - Google Patents

IMUNOGENS CONTAINING PEPTIDES FROM DOMINO CE2 DE IgE FOR THE TREATMENT AND PREVENTION OF ALLERGIC DISEASES

Info

Publication number
CO5210906A1
CO5210906A1 CO00013394A CO00013394A CO5210906A1 CO 5210906 A1 CO5210906 A1 CO 5210906A1 CO 00013394 A CO00013394 A CO 00013394A CO 00013394 A CO00013394 A CO 00013394A CO 5210906 A1 CO5210906 A1 CO 5210906A1
Authority
CO
Colombia
Prior art keywords
ige
treatment
imunogens
domino
prevention
Prior art date
Application number
CO00013394A
Other languages
Spanish (es)
Inventor
Dyson-Judith Miachel
Ellen Greenwood
Mason-Roger Hewitt Lamont-Sean
Gordon Turnell-Ma Randall-Will
Y De Bassols Paulette V Vinals
Original Assignee
Glaxosmithkline Biolog Sa
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9904405.9A external-priority patent/GB9904405D0/en
Priority claimed from GBGB9907151.6A external-priority patent/GB9907151D0/en
Priority claimed from GBGB9910537.1A external-priority patent/GB9910537D0/en
Priority claimed from GBGB9910538.9A external-priority patent/GB9910538D0/en
Priority claimed from GBGB9918603.3A external-priority patent/GB9918603D0/en
Priority claimed from GBGB9918594.4A external-priority patent/GB9918594D0/en
Priority claimed from GBGB9921047.8A external-priority patent/GB9921047D0/en
Priority claimed from GBGB9921046.0A external-priority patent/GB9921046D0/en
Priority claimed from GBGB9925619.0A external-priority patent/GB9925619D0/en
Priority claimed from GBGB9927698.2A external-priority patent/GB9927698D0/en
Application filed by Glaxosmithkline Biolog Sa, Peptide Therapeutics Ltd filed Critical Glaxosmithkline Biolog Sa
Publication of CO5210906A1 publication Critical patent/CO5210906A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un péptido que comprende un epitopo aislado expuesto a la superficie del dominio C?2 de IgE, o mimotopo de éste.1Un inmunógeno para el tratamiento de la alergia que comprende un péptido o mimotopo como el reivindicado encualquiera de las reivindicaciones 1 a 16, que comprende adicionalmente una molécula vehículo.2Un ligando que es capaz de reconocer un epitopo expuesto a la superficie del dominio C?2 de IgE, caracterizado porque el ligando no es PTmAb0005.2Una composición farmacéutica que comprende un ligando que es capaz de reconocer un epitopo expuesto a la superficie del dominio C?2 de IgE.3Un procedimiento de elaboración de una vacuna que comprende la elaboración de un ínmunógeno como el reivindicado en cualquiera de las reivindicaciones 17 a 20, y la formulación del inmunógeno con un coadyuvante.A peptide comprising an isolated epitope exposed to the surface of the C2 domain of IgE, or its mimotope.1 An immunogen for the treatment of allergy comprising a peptide or mimotope as claimed in any of claims 1 to 16, which additionally comprises a carrier molecule.2 A ligand that is capable of recognizing an epitope exposed to the surface of the C? 2 domain of IgE, characterized in that the ligand is not PTmAb0005.2 A pharmaceutical composition comprising a ligand that is capable of recognizing an exposed epitope to the surface of the C? 2 domain of IgE.3 A method of making a vaccine comprising the preparation of an immunogen as claimed in any one of claims 17 to 20, and the formulation of the immunogen with an adjuvant.

CO00013394A 1999-02-25 2000-02-25 IMUNOGENS CONTAINING PEPTIDES FROM DOMINO CE2 DE IgE FOR THE TREATMENT AND PREVENTION OF ALLERGIC DISEASES CO5210906A1 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GBGB9904405.9A GB9904405D0 (en) 1999-02-25 1999-02-25 Vaccine
GBGB9907151.6A GB9907151D0 (en) 1999-03-29 1999-03-29 Therapeutic antibody composition and use
GBGB9910537.1A GB9910537D0 (en) 1999-05-07 1999-05-07 Therapeutic antibody, Immunogenic compositions and uses
GBGB9910538.9A GB9910538D0 (en) 1999-05-07 1999-05-07 Therapeutic antibody, Immunogenic compositions ansd uses
GBGB9918603.3A GB9918603D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918594.4A GB9918594D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9921047.8A GB9921047D0 (en) 1999-09-07 1999-09-07 Therapeutic antibody, immunogenic compositions & uses
GBGB9921046.0A GB9921046D0 (en) 1999-09-07 1999-09-07 Therapeutic antibody composition & use
GBGB9925619.0A GB9925619D0 (en) 1999-10-29 1999-10-29 Vaccine
GBGB9927698.2A GB9927698D0 (en) 1999-11-23 1999-11-23 Therapeutic antibody

Publications (1)

Publication Number Publication Date
CO5210906A1 true CO5210906A1 (en) 2002-10-30

Family

ID=27579426

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00013394A CO5210906A1 (en) 1999-02-25 2000-02-25 IMUNOGENS CONTAINING PEPTIDES FROM DOMINO CE2 DE IgE FOR THE TREATMENT AND PREVENTION OF ALLERGIC DISEASES

Country Status (19)

Country Link
EP (1) EP1155037A1 (en)
JP (1) JP2004538238A (en)
KR (1) KR20020007313A (en)
CN (1) CN1348466A (en)
AR (1) AR029336A1 (en)
AU (1) AU2672700A (en)
BR (1) BR0008963A (en)
CA (1) CA2363637A1 (en)
CO (1) CO5210906A1 (en)
CZ (1) CZ20013082A3 (en)
HK (1) HK1044004A1 (en)
HU (1) HUP0200049A2 (en)
IL (1) IL145024A0 (en)
MX (1) MXPA01008613A (en)
NO (1) NO20014130L (en)
NZ (1) NZ513679A (en)
PL (1) PL350993A1 (en)
TR (1) TR200102506T2 (en)
WO (1) WO2000050460A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913327D0 (en) * 1999-06-08 1999-08-11 Smithkline Beecham Biolog Vaccine
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
AU2002254683C1 (en) * 2001-04-18 2009-01-22 Dyax Corp. Binding molecules for Fc-region polypeptides
GB0209878D0 (en) * 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
AR065368A1 (en) * 2007-02-15 2009-06-03 Astrazeneca Ab ANTIBODIES FOR IGE MOLECULES
US20110212084A1 (en) * 2007-02-15 2011-09-01 Astrazeneca Ab Binding members for ige molecules
ES2615881T3 (en) 2009-05-07 2017-06-08 Stallergenes Use of igg1 immunoglobulins and / or cd32 receptor ligands for the treatment of diseases and inflammatory manifestations through the mucosa.
CA3113604A1 (en) * 2018-09-21 2020-03-26 Riken Anti-ige antibody specifically binding to membrane-bound ige antibody of ige antibody-producing b cells and method for diagnosing and treating allergic symptoms using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4171299A (en) * 1975-04-04 1979-10-16 The Regents Of The University Of California Polypeptide agents for blocking the human allergic response
AU6532498A (en) * 1996-12-06 1998-06-29 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Inhibition of ige-mediated allergies by a human ige-derived oligopeptide
WO1999004265A2 (en) * 1997-07-17 1999-01-28 Ludwig Institute For Cancer Research Cancer associated nucleic acids and polypeptides

Also Published As

Publication number Publication date
CA2363637A1 (en) 2000-08-31
EP1155037A1 (en) 2001-11-21
MXPA01008613A (en) 2003-06-24
AR029336A1 (en) 2003-06-25
CZ20013082A3 (en) 2002-02-13
AU2672700A (en) 2000-09-14
IL145024A0 (en) 2002-06-30
JP2004538238A (en) 2004-12-24
HK1044004A1 (en) 2002-10-04
NO20014130D0 (en) 2001-08-24
TR200102506T2 (en) 2002-06-21
NO20014130L (en) 2001-09-13
WO2000050460A1 (en) 2000-08-31
NZ513679A (en) 2001-09-28
KR20020007313A (en) 2002-01-26
HUP0200049A2 (en) 2002-05-29
CN1348466A (en) 2002-05-08
BR0008963A (en) 2001-11-27
PL350993A1 (en) 2003-02-24

Similar Documents

Publication Publication Date Title
BR0016022A (en) Vaccine for the prevention and treatment of alzheimer's disease and amyloid-related diseases
DE69718150T2 (en) PEPTID IMMUNOGENES FOR VACCINATION AGAINST AND TREATMENT OF ALLERGIES
EA200000608A1 (en) PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
ATE468137T1 (en) INHIBITORS OF HMGB1 FOR THE TREATMENT OF TISSUE DISEASES
ES2072323T3 (en) PIPERIDINE COMPOUNDS AND THEIR PREPARATION AND USE.
DE69836822D1 (en) Process for the treatment of capsules and dry powdered pharmaceutical formulations
DE60029799D1 (en) COMPOUNDS, PROCESSES AND PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CELL DAMAGE SUCH AS, FOR EXAMPLE, DAMAGE TO NERVE OR CANDLE TISSUE
DE69727158D1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A MIXTURE OF SELF-CROSS-LINKED AND NON-SELF-CROSSLINKED HYALURONIC ACID FOR THE TREATMENT OF ARTHROPATHIES
ATE242633T1 (en) DIALKYLFUMARATE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
ES2231826T3 (en) ANTI-CD6 MONOCLONAL ANTIBODIES FOR THE TREATMENT AND DIAGNOSIS OF PSORIASIS.
AR031975A1 (en) ANALOG COMPOUNDS OF (1R, CIS) -4- (6-AMINO-9H-PURIN-9-IL) -2-CYCLOPENTENE-1-METHANOL, PROCESS FOR PREPARATION, USE IN THE TREATMENT OF VIRAL INFECTIONS, AND PACKING THAT CONTAINS THEM
ATE218581T1 (en) CYCLOSPORINE DERIVATIVE, PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION
AR023806A1 (en) USE OF A PEPTIDE MIXTURE FOR THE MANUFACTURE OF A THERAPEUTIC AGENT FOR PROFILAXIS AND / OR CANCER TREATMENT, PHARMACEUTICAL COMPOSITIONS AND VACCINES CONTAINING SUCH MIXTURE AND THE PROCEDURES FOR PREPARATION OF THESE COMPOSITIONS
ATE108334T1 (en) IMMUNOTHERAPEUTIC PREPARATIONS FOR THE TREATMENT OF AIDS.
AR003589A1 (en) USE OF AN EFFECTIVE AMOUNT OF AT LEAST ONE PEPTIDE IN A COSMETIC COMPOSITION OR FOR THE PREPARATION OF A MEDICATION INTENDED TO PARATRATE INFLAMMATION, AND A COSMETIC TREATMENT PROCEDURE THROUGH A COSMETIC COMPOSITION CONTAINING SUCH PEPTIDE.
ES2044514T3 (en) ALOE WATER, PREPARATION PROCEDURE AND COMPOSITIONS THAT CONTAIN IT.
AR008799A1 (en) VACCINE COMPOSITION TO PREVENT OR TREAT MALARIA; USE OF SUCH COMPOSITION TO PREPARE DRUGS AND METHOD FOR SUCH PROPHYLAXIS AND SUCH TREATMENT
ES2177636T3 (en) USE OF EMPOBRECIDE WATER IN DEUTERIO IN THE PREPARATION OF COSMETICS.
BR0211761A (en) depsipeptides and processes for preparing them
CO5210906A1 (en) IMUNOGENS CONTAINING PEPTIDES FROM DOMINO CE2 DE IgE FOR THE TREATMENT AND PREVENTION OF ALLERGIC DISEASES
DE60136826D1 (en) USE OF ASICIC ACID OR ASICATICOSIDE FOR THE TREATMENT OF CANCER
ES2096988T3 (en) ORGANOPOLISILOXANES CONTAINING HYDROPHILUS GROUPS.
ATE107859T1 (en) USE OF ANTIPROGESTOMIMETICS TO STIMULATE OVULATION.
ES2158857T3 (en) STREPTOQUINASE-BASED VACCINES.
DE68905076D1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SKIN Wounds.

Legal Events

Date Code Title Description
FC Application refused